Henogen Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Charleroi Belgium (1999)
Status: Acquired by Novasep (2009)

Organization Overview

First Clinical Trial
2006
NCT00291941
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Shenzhen Hemogen

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6